Wielgos-Bonvallet, Monica
Genmab (United States) · Genmab (Netherlands) · Genmab (Denmark)
3 papers on CoChatORCID 0009-0007-0009-2629
Most cited papers
- Verified
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Mhibik, M., Gaglione, E. M., Eik, D., Herrick, J., Le, J., Ahn, I. E., Chiu, C., Wielgos-Bonvallet, M., Hiemstra, I. H., Breij, E. C. W., et al. (2023) · Blood Advances
Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment
Cited by 43
- Verified
Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1
Vose, J. M., Feldman, T., Chamuleau, M. E. D., Kim, W. S., Lugtenburg, P., Kim, T. M., Costa, P. A., Cheah, C. Y., Glimelius, I. C., Hess, B., et al. (2023) · Blood
Lymphoma Diagnosis and TreatmentCAR-T cell therapy research
Cited by 14
- Verified
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma
Dandamudi, D. B., Konieczna, I. M., Calabrese, K. M., Wielgos-Bonvallet, M., Kweekel, C., Gresnigt-van den Heuvel, E., Iyer, R., Ellis, P., Rodriguez, L., Parikh, A., et al. (2025) · Leukemia & Lymphoma
Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research
Cited by 5
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free